Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, E…
$166.89-0.41%
报价 2026-11-06
市值
$207B
EV
$187.52B
PE (TTM)
20.0x
预期 PE (FY2026)
–
52 周区间距高点 -4.4%
$118.15$174.48
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 8.45 → 10.10（1.2x） | 16.5 |
| FY+32028-12 | 1.1x | 8.45 → 10.78（1.3x） | 15.5 |
毛利率 81% · TTM 收入 $30987M · 基数 EPS 8.45（调整后）
一次性亏损已剔除
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| GILDGilead Sciences, Inc. | $207B | -0.4% | +4.1% | 81.1% | 20.0x | 14.5x | 21.9x | |
| MRKMerck & Co., Inc. | $361.96B | -0.2% | +3.6% | 73.5% | 121.5x | 30.7x | 23.5x | |
| AMGNAmgen Inc. | $248.92B | +0.0% | +4.0% | 70.5% | 24.4x | 12.5x | 30.7x | |
| NVONovo Nordisk A/S | $177.74B | +0.0% | – | 78.2% | 10.3x | 7.2x | – | Cheap |
| PFEPfizer Inc. | $167.51B | -0.2% | +1.4% | 72.8% | 37.3x | 17.7x | 14.7x | |
| DHRDanaher Corporation | $161.86B | +1.7% | +3.8% | 60.9% | 37.2x | 21.3x | 30.8x | |
| BMYBristol-Myers Squibb Company PFD CONV 2 | $127.02B | -1.6% | -1.5% | 67.7% | 16.5x | 10.5x | 9.9x | |
| SYKStryker Corporation | $124.02B | -2.8% | +8.8% | 63.5% | 39.2x | 24.7x | 28.9x | |
| SNYSanofi | $113.26B | +0.3% | – | 71.7% | 8.9x | 9.7x | – | |
| 同行中位数 | – | – | +3.7% | 71.1% | 30.8x | 15.1x | 26.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.3B | $7.8B | $6.96B | $7.92B | $7.77B | $7.08B | $6.67B | $7.57B |
| Gross Margin | 81.1% | 79.8% | 79.2% | 79.5% | 79.8% | 78.8% | 76.9% | 79.1% |
| Operating Margin | 41.7% | -133.2% | 37.2% | 37.7% | 42.8% | 34.9% | 33.6% | 32.4% |
| Net Income | $2.43B | $-10.5B | $2.02B | $2.18B | $3.05B | $1.96B | $1.32B | $1.78B |
| Diluted EPS | 1.94 | -8.45 | 1.61 | 1.74 | 2.43 | 1.56 | 1.04 | 1.42 |
| Operating Cash Flow | $5.04B | $3.57B | $2.54B | $3.33B | $4.11B | $827M | $1.76B | $2.98B |